Treatment of queens in estrus and after estrus with a GnRH-agonist implant containing 4.7 mg deslorelin; hormonal response, duration of efficacy, and reversibility

Although slow release GnRH-agonist implants have been shown to effectively suppress the estrous cycle in queens, there are still several remaining questions about their use: if the probability and frequency of estrus induction because of initial stimulation is dependent on the stage of cycle when an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Theriogenology 2013-03, Vol.79 (4), p.640-646
Hauptverfasser: Goericke-Pesch, Sandra, Georgiev, Plamen, Atanasov, Anatoli, Albouy, Maxime, Navarro, Christelle, Wehrend, Axel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 646
container_issue 4
container_start_page 640
container_title Theriogenology
container_volume 79
creator Goericke-Pesch, Sandra
Georgiev, Plamen
Atanasov, Anatoli
Albouy, Maxime
Navarro, Christelle
Wehrend, Axel
description Although slow release GnRH-agonist implants have been shown to effectively suppress the estrous cycle in queens, there are still several remaining questions about their use: if the probability and frequency of estrus induction because of initial stimulation is dependent on the stage of cycle when animals are treated, if all effects are reversible, and to what extent fertility is regained after the end of efficacy. The latter is of major interest to cat breeders who want temporary suppression of estrus in breeding animals. Twenty queens (14 with known fertility) were treated with a 4.7 mg deslorelin implant; hormonal changes (progesterone [P4], and estradiol [E2]) and behavioral changes with special respect to estrus signs and subsequent fertility were assessed. Group A cats (N = 10) were treated 3.2 ± 0.8 days after the beginning of estrus and estrus stopped 4.1 ± 2.5 days after treatment. Estrus induction was observed in one queen 6 days after treatment, and one queen showed estrous signs 138 and 155 days after treatment. Progesterone increased significantly after treatment in all animals until day 14, then slowly decreased reaching basal levels on day 56 without any further increase. Group B cats (N = 10) were treated 7 days after the end of estrus; nine cats had P4 > 1.5 ng/mL and basal E2, one cat (B10) had basal E2 and P4. In cat B10 estrus induction occurred after treatment, but in none of the others; however, E2 increased in all group B cats 1 day after treatment but reached pretreatment concentrations on Day 7 again and remained basal. The implant was still effective in one animal of the estrus group with a duration of efficacy >1102 days, in the others duration of efficacy varied between 483 and 1025 days. Eight queens were mated afterwards and gave birth to a healthy litter with 3.3 ± 1.5 kittens. This study proves that (1) the incidence of estrus induction—although very low—is highest after treatment in estrus or postestrus, (2) the duration of efficacy varies between 16 and 37 months, and (3) estrus suppression is reversible and animals remain fertile after the treatment effect has expired.
doi_str_mv 10.1016/j.theriogenology.2012.11.018
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1284291040</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0093691X12006176</els_id><sourcerecordid>1284291040</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-86256a1814c5874bcf1a6dd1320a55af36dd805b14f287bf78d3edc3d6b67e0a3</originalsourceid><addsrcrecordid>eNqNkc-KFDEQh4Mo7jr6CpqDBw_bbSrpv-hFFndXWBB0F7yFdFLpydCdjElmZZ7HF7XH2RW8iKeQ8NWvKvUR8hpYCQyat5syrzG6MKIPUxj3JWfAS4CSQfeInELX9oXgAh6TU8Z6UTQ9fDshz1LaMMZE08BTcsIFb-pesFPy8yaiyjP6TIOl33eIPlHnKaYcd4kqb6iyGePDww-X11TRS__lqlBj8C5l6ubtpJYAHXxWzjs_0qps6TxSg2kKESfn39F1iHPwaqIR0zb4hGfU7KLKLvhDa7TWaaX3Z797RrzDmNzgJpf3z8kTq6aEL-7PFbm9-HhzflVcf778dP7hutCVqHLRNbxuFHRQ6bprq0FbUI0xIDhTda2sWC4dqweoLO_awbadEWi0MM3QtMiUWJE3x9xtDMsmUpazSxqn5XMYdkkC7yreA6vYgr4_ojqGlCJauY1uVnEvgcmDJrmRf2uSB00SQC6alvKX9512w4zmT_GDlwV4dQSsClKN0SV5-3VJqA4OW151_ySgP5hfkYsjgcvO7hxGmbRDr9G4iDpLE9z_TfsLc-zCTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1284291040</pqid></control><display><type>article</type><title>Treatment of queens in estrus and after estrus with a GnRH-agonist implant containing 4.7 mg deslorelin; hormonal response, duration of efficacy, and reversibility</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Goericke-Pesch, Sandra ; Georgiev, Plamen ; Atanasov, Anatoli ; Albouy, Maxime ; Navarro, Christelle ; Wehrend, Axel</creator><creatorcontrib>Goericke-Pesch, Sandra ; Georgiev, Plamen ; Atanasov, Anatoli ; Albouy, Maxime ; Navarro, Christelle ; Wehrend, Axel</creatorcontrib><description>Although slow release GnRH-agonist implants have been shown to effectively suppress the estrous cycle in queens, there are still several remaining questions about their use: if the probability and frequency of estrus induction because of initial stimulation is dependent on the stage of cycle when animals are treated, if all effects are reversible, and to what extent fertility is regained after the end of efficacy. The latter is of major interest to cat breeders who want temporary suppression of estrus in breeding animals. Twenty queens (14 with known fertility) were treated with a 4.7 mg deslorelin implant; hormonal changes (progesterone [P4], and estradiol [E2]) and behavioral changes with special respect to estrus signs and subsequent fertility were assessed. Group A cats (N = 10) were treated 3.2 ± 0.8 days after the beginning of estrus and estrus stopped 4.1 ± 2.5 days after treatment. Estrus induction was observed in one queen 6 days after treatment, and one queen showed estrous signs 138 and 155 days after treatment. Progesterone increased significantly after treatment in all animals until day 14, then slowly decreased reaching basal levels on day 56 without any further increase. Group B cats (N = 10) were treated 7 days after the end of estrus; nine cats had P4 &gt; 1.5 ng/mL and basal E2, one cat (B10) had basal E2 and P4. In cat B10 estrus induction occurred after treatment, but in none of the others; however, E2 increased in all group B cats 1 day after treatment but reached pretreatment concentrations on Day 7 again and remained basal. The implant was still effective in one animal of the estrus group with a duration of efficacy &gt;1102 days, in the others duration of efficacy varied between 483 and 1025 days. Eight queens were mated afterwards and gave birth to a healthy litter with 3.3 ± 1.5 kittens. This study proves that (1) the incidence of estrus induction—although very low—is highest after treatment in estrus or postestrus, (2) the duration of efficacy varies between 16 and 37 months, and (3) estrus suppression is reversible and animals remain fertile after the treatment effect has expired.</description><identifier>ISSN: 0093-691X</identifier><identifier>EISSN: 1879-3231</identifier><identifier>DOI: 10.1016/j.theriogenology.2012.11.018</identifier><identifier>PMID: 23265930</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>animal breeding ; Animals ; Cats - physiology ; Contraception - methods ; Contraception - veterinary ; Contraceptive Agents, Female - administration &amp; dosage ; Drug Implants ; Duration of efficacy ; Estradiol - blood ; Estrus ; Estrus induction ; Female ; Fertility ; GnRH-agonist ; Gonadotropin-Releasing Hormone - agonists ; kittens ; parturition ; Pregnancy ; probability ; progesterone ; Progesterone - blood ; Reversibility ; Triptorelin Pamoate - administration &amp; dosage ; Triptorelin Pamoate - analogs &amp; derivatives</subject><ispartof>Theriogenology, 2013-03, Vol.79 (4), p.640-646</ispartof><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-86256a1814c5874bcf1a6dd1320a55af36dd805b14f287bf78d3edc3d6b67e0a3</citedby><cites>FETCH-LOGICAL-c434t-86256a1814c5874bcf1a6dd1320a55af36dd805b14f287bf78d3edc3d6b67e0a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.theriogenology.2012.11.018$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23265930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goericke-Pesch, Sandra</creatorcontrib><creatorcontrib>Georgiev, Plamen</creatorcontrib><creatorcontrib>Atanasov, Anatoli</creatorcontrib><creatorcontrib>Albouy, Maxime</creatorcontrib><creatorcontrib>Navarro, Christelle</creatorcontrib><creatorcontrib>Wehrend, Axel</creatorcontrib><title>Treatment of queens in estrus and after estrus with a GnRH-agonist implant containing 4.7 mg deslorelin; hormonal response, duration of efficacy, and reversibility</title><title>Theriogenology</title><addtitle>Theriogenology</addtitle><description>Although slow release GnRH-agonist implants have been shown to effectively suppress the estrous cycle in queens, there are still several remaining questions about their use: if the probability and frequency of estrus induction because of initial stimulation is dependent on the stage of cycle when animals are treated, if all effects are reversible, and to what extent fertility is regained after the end of efficacy. The latter is of major interest to cat breeders who want temporary suppression of estrus in breeding animals. Twenty queens (14 with known fertility) were treated with a 4.7 mg deslorelin implant; hormonal changes (progesterone [P4], and estradiol [E2]) and behavioral changes with special respect to estrus signs and subsequent fertility were assessed. Group A cats (N = 10) were treated 3.2 ± 0.8 days after the beginning of estrus and estrus stopped 4.1 ± 2.5 days after treatment. Estrus induction was observed in one queen 6 days after treatment, and one queen showed estrous signs 138 and 155 days after treatment. Progesterone increased significantly after treatment in all animals until day 14, then slowly decreased reaching basal levels on day 56 without any further increase. Group B cats (N = 10) were treated 7 days after the end of estrus; nine cats had P4 &gt; 1.5 ng/mL and basal E2, one cat (B10) had basal E2 and P4. In cat B10 estrus induction occurred after treatment, but in none of the others; however, E2 increased in all group B cats 1 day after treatment but reached pretreatment concentrations on Day 7 again and remained basal. The implant was still effective in one animal of the estrus group with a duration of efficacy &gt;1102 days, in the others duration of efficacy varied between 483 and 1025 days. Eight queens were mated afterwards and gave birth to a healthy litter with 3.3 ± 1.5 kittens. This study proves that (1) the incidence of estrus induction—although very low—is highest after treatment in estrus or postestrus, (2) the duration of efficacy varies between 16 and 37 months, and (3) estrus suppression is reversible and animals remain fertile after the treatment effect has expired.</description><subject>animal breeding</subject><subject>Animals</subject><subject>Cats - physiology</subject><subject>Contraception - methods</subject><subject>Contraception - veterinary</subject><subject>Contraceptive Agents, Female - administration &amp; dosage</subject><subject>Drug Implants</subject><subject>Duration of efficacy</subject><subject>Estradiol - blood</subject><subject>Estrus</subject><subject>Estrus induction</subject><subject>Female</subject><subject>Fertility</subject><subject>GnRH-agonist</subject><subject>Gonadotropin-Releasing Hormone - agonists</subject><subject>kittens</subject><subject>parturition</subject><subject>Pregnancy</subject><subject>probability</subject><subject>progesterone</subject><subject>Progesterone - blood</subject><subject>Reversibility</subject><subject>Triptorelin Pamoate - administration &amp; dosage</subject><subject>Triptorelin Pamoate - analogs &amp; derivatives</subject><issn>0093-691X</issn><issn>1879-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc-KFDEQh4Mo7jr6CpqDBw_bbSrpv-hFFndXWBB0F7yFdFLpydCdjElmZZ7HF7XH2RW8iKeQ8NWvKvUR8hpYCQyat5syrzG6MKIPUxj3JWfAS4CSQfeInELX9oXgAh6TU8Z6UTQ9fDshz1LaMMZE08BTcsIFb-pesFPy8yaiyjP6TIOl33eIPlHnKaYcd4kqb6iyGePDww-X11TRS__lqlBj8C5l6ubtpJYAHXxWzjs_0qps6TxSg2kKESfn39F1iHPwaqIR0zb4hGfU7KLKLvhDa7TWaaX3Z797RrzDmNzgJpf3z8kTq6aEL-7PFbm9-HhzflVcf778dP7hutCVqHLRNbxuFHRQ6bprq0FbUI0xIDhTda2sWC4dqweoLO_awbadEWi0MM3QtMiUWJE3x9xtDMsmUpazSxqn5XMYdkkC7yreA6vYgr4_ojqGlCJauY1uVnEvgcmDJrmRf2uSB00SQC6alvKX9512w4zmT_GDlwV4dQSsClKN0SV5-3VJqA4OW151_ySgP5hfkYsjgcvO7hxGmbRDr9G4iDpLE9z_TfsLc-zCTQ</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>Goericke-Pesch, Sandra</creator><creator>Georgiev, Plamen</creator><creator>Atanasov, Anatoli</creator><creator>Albouy, Maxime</creator><creator>Navarro, Christelle</creator><creator>Wehrend, Axel</creator><general>Elsevier Inc</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130301</creationdate><title>Treatment of queens in estrus and after estrus with a GnRH-agonist implant containing 4.7 mg deslorelin; hormonal response, duration of efficacy, and reversibility</title><author>Goericke-Pesch, Sandra ; Georgiev, Plamen ; Atanasov, Anatoli ; Albouy, Maxime ; Navarro, Christelle ; Wehrend, Axel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-86256a1814c5874bcf1a6dd1320a55af36dd805b14f287bf78d3edc3d6b67e0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>animal breeding</topic><topic>Animals</topic><topic>Cats - physiology</topic><topic>Contraception - methods</topic><topic>Contraception - veterinary</topic><topic>Contraceptive Agents, Female - administration &amp; dosage</topic><topic>Drug Implants</topic><topic>Duration of efficacy</topic><topic>Estradiol - blood</topic><topic>Estrus</topic><topic>Estrus induction</topic><topic>Female</topic><topic>Fertility</topic><topic>GnRH-agonist</topic><topic>Gonadotropin-Releasing Hormone - agonists</topic><topic>kittens</topic><topic>parturition</topic><topic>Pregnancy</topic><topic>probability</topic><topic>progesterone</topic><topic>Progesterone - blood</topic><topic>Reversibility</topic><topic>Triptorelin Pamoate - administration &amp; dosage</topic><topic>Triptorelin Pamoate - analogs &amp; derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goericke-Pesch, Sandra</creatorcontrib><creatorcontrib>Georgiev, Plamen</creatorcontrib><creatorcontrib>Atanasov, Anatoli</creatorcontrib><creatorcontrib>Albouy, Maxime</creatorcontrib><creatorcontrib>Navarro, Christelle</creatorcontrib><creatorcontrib>Wehrend, Axel</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Theriogenology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goericke-Pesch, Sandra</au><au>Georgiev, Plamen</au><au>Atanasov, Anatoli</au><au>Albouy, Maxime</au><au>Navarro, Christelle</au><au>Wehrend, Axel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of queens in estrus and after estrus with a GnRH-agonist implant containing 4.7 mg deslorelin; hormonal response, duration of efficacy, and reversibility</atitle><jtitle>Theriogenology</jtitle><addtitle>Theriogenology</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>79</volume><issue>4</issue><spage>640</spage><epage>646</epage><pages>640-646</pages><issn>0093-691X</issn><eissn>1879-3231</eissn><abstract>Although slow release GnRH-agonist implants have been shown to effectively suppress the estrous cycle in queens, there are still several remaining questions about their use: if the probability and frequency of estrus induction because of initial stimulation is dependent on the stage of cycle when animals are treated, if all effects are reversible, and to what extent fertility is regained after the end of efficacy. The latter is of major interest to cat breeders who want temporary suppression of estrus in breeding animals. Twenty queens (14 with known fertility) were treated with a 4.7 mg deslorelin implant; hormonal changes (progesterone [P4], and estradiol [E2]) and behavioral changes with special respect to estrus signs and subsequent fertility were assessed. Group A cats (N = 10) were treated 3.2 ± 0.8 days after the beginning of estrus and estrus stopped 4.1 ± 2.5 days after treatment. Estrus induction was observed in one queen 6 days after treatment, and one queen showed estrous signs 138 and 155 days after treatment. Progesterone increased significantly after treatment in all animals until day 14, then slowly decreased reaching basal levels on day 56 without any further increase. Group B cats (N = 10) were treated 7 days after the end of estrus; nine cats had P4 &gt; 1.5 ng/mL and basal E2, one cat (B10) had basal E2 and P4. In cat B10 estrus induction occurred after treatment, but in none of the others; however, E2 increased in all group B cats 1 day after treatment but reached pretreatment concentrations on Day 7 again and remained basal. The implant was still effective in one animal of the estrus group with a duration of efficacy &gt;1102 days, in the others duration of efficacy varied between 483 and 1025 days. Eight queens were mated afterwards and gave birth to a healthy litter with 3.3 ± 1.5 kittens. This study proves that (1) the incidence of estrus induction—although very low—is highest after treatment in estrus or postestrus, (2) the duration of efficacy varies between 16 and 37 months, and (3) estrus suppression is reversible and animals remain fertile after the treatment effect has expired.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23265930</pmid><doi>10.1016/j.theriogenology.2012.11.018</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0093-691X
ispartof Theriogenology, 2013-03, Vol.79 (4), p.640-646
issn 0093-691X
1879-3231
language eng
recordid cdi_proquest_miscellaneous_1284291040
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects animal breeding
Animals
Cats - physiology
Contraception - methods
Contraception - veterinary
Contraceptive Agents, Female - administration & dosage
Drug Implants
Duration of efficacy
Estradiol - blood
Estrus
Estrus induction
Female
Fertility
GnRH-agonist
Gonadotropin-Releasing Hormone - agonists
kittens
parturition
Pregnancy
probability
progesterone
Progesterone - blood
Reversibility
Triptorelin Pamoate - administration & dosage
Triptorelin Pamoate - analogs & derivatives
title Treatment of queens in estrus and after estrus with a GnRH-agonist implant containing 4.7 mg deslorelin; hormonal response, duration of efficacy, and reversibility
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T05%3A03%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20queens%20in%20estrus%20and%20after%20estrus%20with%20a%20GnRH-agonist%20implant%20containing%204.7%20mg%20deslorelin;%20hormonal%20response,%20duration%20of%20efficacy,%20and%20reversibility&rft.jtitle=Theriogenology&rft.au=Goericke-Pesch,%20Sandra&rft.date=2013-03-01&rft.volume=79&rft.issue=4&rft.spage=640&rft.epage=646&rft.pages=640-646&rft.issn=0093-691X&rft.eissn=1879-3231&rft_id=info:doi/10.1016/j.theriogenology.2012.11.018&rft_dat=%3Cproquest_cross%3E1284291040%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1284291040&rft_id=info:pmid/23265930&rft_els_id=S0093691X12006176&rfr_iscdi=true